5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and Vomiting
- 1 January 1998
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 55 (2) , 173-189
Abstract
In the mid-1980s it was discovered that serotonin (5-hydroxytryptamine; 5-HT) was at least partially responsible for producing chemotherapy-induced nausea and vomiting. It was therefore realised that...Keywords
This publication has 52 references indexed in Scilit:
- Physiology of Chemotherapy-Induced Emesis and Antiemetic TherapyDrugs, 1997
- Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapyEuropean Journal of Cancer, 1996
- 5-HT3Receptors: Pharmacologic and Therapeutic AspectsThe Journal of Clinical Pharmacology, 1995
- A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preferenceEuropean Journal of Cancer, 1994
- TropisetronDrugs, 1993
- 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—A randomised studyEuropean Journal of Cancer, 1993
- Are all 5-HT3 receptor antagonists the same?European Journal of Cancer, 1992
- TropisetronDrugs, 1992
- Optimum Management of Nausea and Vomiting in Cancer ChemotherapyDrugs, 1987
- Fifteen-Year Follow-up of Hyperoxaluria Type IINew England Journal of Medicine, 1983